Archford Capital Strategies LLC Decreases Stock Holdings in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Archford Capital Strategies LLC trimmed its holdings in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 13.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,596 shares of the company’s stock after selling 718 shares during the quarter. Archford Capital Strategies LLC owned about 0.11% of Invesco Biotechnology & Genome ETF worth $306,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Cetera Investment Advisers increased its holdings in shares of Invesco Biotechnology & Genome ETF by 2.1% during the 2nd quarter. Cetera Investment Advisers now owns 27,893 shares of the company’s stock worth $1,808,000 after buying an additional 561 shares during the last quarter. Massachusetts Wealth Management increased its holdings in shares of Invesco Biotechnology & Genome ETF by 7.3% during the 3rd quarter. Massachusetts Wealth Management now owns 18,184 shares of the company’s stock worth $1,270,000 after buying an additional 1,240 shares during the last quarter. IHT Wealth Management LLC increased its holdings in shares of Invesco Biotechnology & Genome ETF by 14.7% during the 3rd quarter. IHT Wealth Management LLC now owns 12,124 shares of the company’s stock worth $847,000 after buying an additional 1,550 shares during the last quarter. HighTower Advisors LLC increased its holdings in shares of Invesco Biotechnology & Genome ETF by 64.1% during the 3rd quarter. HighTower Advisors LLC now owns 7,101 shares of the company’s stock worth $494,000 after buying an additional 2,774 shares during the last quarter. Finally, Creative Financial Designs Inc. ADV increased its holdings in shares of Invesco Biotechnology & Genome ETF by 5.6% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 5,630 shares of the company’s stock worth $393,000 after buying an additional 299 shares during the last quarter.

Invesco Biotechnology & Genome ETF Price Performance

Shares of NYSEARCA PBE opened at $69.04 on Monday. The company has a 50 day simple moving average of $68.49 and a 200-day simple moving average of $69.17. The company has a market capitalization of $278.92 million, a P/E ratio of 17.12 and a beta of 0.88. Invesco Biotechnology & Genome ETF has a 1 year low of $59.32 and a 1 year high of $72.84.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.